文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

新型冠状病毒感染相关急性呼吸窘迫综合征患者中的肺部单纯疱疹病毒与巨细胞病毒

Pulmonary herpes simplex virus and cytomegalovirus in patients with acute respiratory distress syndrome related to COVID-19.
PubMed 文献 · Intensive Care Med · 2024-07-17
一句话结论机械通气的新型冠状病毒感染相关急性呼吸窘迫综合征患者中,单纯疱疹病毒再激活常见(37%),其病毒载量动态与90天死亡率升高相关(HR 1.24)。

这项观察性队列研究纳入对巨细胞病毒或单纯疱疹病毒血清学阳性的机械通气新型冠状病毒感染患者,常规行支气管镜肺泡灌洗检测肺泡病毒载量和炎症生物标志物,采用联合模型分析病毒载量轨迹与死亡率的动态关联。结果显示,巨细胞病毒再激活(>10^4拷贝/ml)发生于6%的巨细胞病毒血清学阳性患者(9/156),单纯疱疹病毒再激活发生于37%的单纯疱疹病毒血清学阳性患者(63/172)。抗病毒治疗前或未抗病毒治疗期间的单纯疱疹病毒载量动态与90天死亡率升高相关(HR 1.24,95%CI 1.04-1.47)。单纯疱疹病毒再激活后肺泡白细胞介素-6、白细胞介素-1β、粒细胞集落刺激因子和肿瘤坏死因子等炎症生物标志物浓度升高。

要点

  • 机械通气的新型冠状病毒感染相关急性呼吸窘迫综合征患者中,单纯疱疹病毒再激活(>10^4拷贝/ml)见于37%的单纯疱疹病毒血清学阳性患者(63/172)。
  • 巨细胞病毒再激活(>10^4拷贝/ml)仅见于6%的巨细胞病毒血清学阳性患者(9/156),相对少见。
  • 抗病毒治疗前或未抗病毒治疗期间的单纯疱疹病毒载量动态与90天死亡率升高相关(HR 1.24,95%CI 1.04-1.47)。
  • 单纯疱疹病毒再激活后肺泡炎症生物标志物升高,包括白细胞介素-6、白细胞介素-1β、粒细胞集落刺激因子和肿瘤坏死因子。

适用人群与场景

  • 对巨细胞病毒或单纯疱疹病毒血清学阳性的机械通气新型冠状病毒感染患者。

诊断标准与关键阈值

  • 肺部再激活定义为肺泡病毒载量>10^4拷贝/ml。

研究设计与关键结果

  • 观察性队列研究中,机械通气的新型冠状病毒感染患者常规行支气管镜肺泡灌洗,检测肺泡病毒载量和炎症生物标志物。
  • 巨细胞病毒再激活(>10^4拷贝/ml)发生于6%的巨细胞病毒血清学阳性患者(9/156)。
  • 单纯疱疹病毒再激活(>10^4拷贝/ml)发生于37%的单纯疱疹病毒血清学阳性患者(63/172)。
  • 抗病毒治疗前或未抗病毒治疗期间的单纯疱疹病毒载量动态与90天死亡率升高相关(HR 1.24,95%CI 1.04-1.47)。
  • 单纯疱疹病毒再激活后肺泡白细胞介素-6、白细胞介素-1β、粒细胞集落刺激因子和肿瘤坏死因子浓度升高。

证据类型、等级与局限

  • 证据类型:观察性队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 原文未据此给出推荐。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

PURPOSE: Human herpesviruses, particularly cytomegalovirus (CMV) and herpes simplex virus (HSV), frequently reactivate in critically ill patients, including those with acute respiratory distress syndrome (ARDS) related to coronavirus disease 2019 (COVID-19). The clinical interpretation of pulmonary herpesvirus reactivation is challenging and there is ongoing debate about its association with mortality and benefit of antiviral medication. We aimed to quantify the incidence and pathogenicity of pulmonary CMV and HSV reactivations in critically ill COVID-19 patients.

METHODS: Mechanically ventilated COVID-19 patients seropositive for CMV or HSV were included in this observational cohort study. Diagnostic bronchoscopy with bronchoalveolar lavage was performed routinely and analyzed for alveolar viral loads and inflammatory biomarkers. Utilizing joint modeling, we explored the dynamic association between viral load trajectories over time and mortality. We explored alveolar inflammatory biomarker dynamics between reactivated and non-reactivated patients.

RESULTS: Pulmonary reactivation (> 104 copies/ml) of CMV occurred in 6% of CMV-seropositive patients (9/156), and pulmonary reactivation of HSV in 37% of HSV-seropositive patients (63/172). HSV viral load dynamics prior to or without antiviral treatment were associated with increased 90-day mortality (hazard ratio [HR] 1.24, 95% confidence interval [CI] 1.04-1.47). The alveolar concentration of several inflammatory biomarkers increased with HSV reactivation, including interleukin (IL)-6, IL-1β, granulocyte colony stimulating factor (G-CSF), and tumor necrosis factor (TNF).

CONCLUSION: In mechanically ventilated COVID-19 patients, HSV reactivations are common, while CMV reactivations were rare. HSV viral load dynamics prior to or without antiviral treatment are associated with mortality. Alveolar inflammation is elevated after HSV reactivation.

来源:Intensive Care Med,查看原文。版权归原作者所有。

参考来源

  1. Boers LS, van Someren Gréve F, van Hattem JM, et al. Pulmonary herpes simplex virus and cytomegalovirus in patients with acute respiratory distress syndrome related to COVID-19. Intensive Care Med. 2024. PMID: 39017695. doi:10.1007/s00134-024-07529-x

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。